FDA approves label updates for BMS’ CAR T cell therapies
Pharmaceutical Technology
JUNE 27, 2025
Last month, European Commission approved the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) with a dosage strength of 600 mg/vial, expanding treatment options for various adult solid tumours. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Let's personalize your content